RxDoctor Payments Data

Angelica Martinez, APRN

Family · Eagle Pass, TXNPI 1144723859

Payments from drug & device makers

$1,951in general payments, 2019–2025

Across 91 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$507
  • Novo Nordisk$466
  • Lilly USA, LLC$377
  • Bayer$127
  • Boehringer Ingelheim$125
  • Boston Scientific$80
  • plus $269 from 9 others

What the payments were for

  • Food & beverage$1,951100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,951 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$17,906
Medicare patients
38
Services billed
316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$211,858
JardianceEmpagliflozin112$127,003
FarxigaDapagliflozin Propanediol50$67,021
Synjardy XrEmpagliflozin/Metformin Hcl74$57,143
JanuviaSitagliptin Phosphate33$47,371
MounjaroTirzepatide38$44,329
RybelsusSemaglutide28$42,219
TradjentaLinagliptin32$31,981
MyrbetriqMirabegron24$24,488
XareltoRivaroxaban12$16,159
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$14,241
LinzessLinaclotide17$12,410
BelsomraSuvorexant17$7,652
SymbicortBudesonide/Formoterol Fumarate14$3,095
Famotidine22$2,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$466$254,077182 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$125$216,127218 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$507$84,35782 claims
MerckJanuvia, Belsomra$14$55,02350 claims
Lilly USA, LLCMounjaro$377$44,32938 claims
Astellas Pharma US IncMyrbetriq$14$24,48824 claims
AbbVieLinzess, Synthroid$48$14,74449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Eagle Pass

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →